Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.54 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.54 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.53 |
| ▸ | DRD3 | P35462 | 1/20 | 0.50 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.46 |
| ▸ | KDM1A | O60341 | 2/20 | 0.44 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | HTR7 | P34969 | 3/20 | 0.41 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.40 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23823660 | 0.86 | CYP1A2 (0.64) | CYP1A2TDP1PIK3CDDRD3HRH3 | |
| SCHEMBL298255 | 0.82 | PIK3CD (0.57) | CYP1A2TDP1PIK3CDDRD3HRH3 | |
| SCHEMBL2619225 | 0.80 | CYP1A2 (0.56) | CYP1A2TDP1PIK3CDDRD3HRH3 | |
| SCHEMBL378022 | 0.80 | CYP1A2 (0.56) | CYP1A2TDP1PIK3CDDRD3HRH3 | |
| SCHEMBL297533 | 0.80 | CYP1A2 (0.56) | CYP1A2TDP1PIK3CDDRD3HRH3 | |
| SCHEMBL13589531 | 0.78 | CYP1A2 (0.54) | CYP1A2TDP1PIK3CDDRD3HRH3 | |
| SCHEMBL296688 | 0.78 | CYP1A2 (0.54) | CYP1A2TDP1PIK3CDDRD3HRH3 | |
| SCHEMBL20961902 | 0.78 | CYP1A2 (0.54) | CYP1A2TDP1PIK3CDDRD3HRH3 | |
| Hydrochloric Acid SCHEMBL20261838 | 0.78 | CYP1A2 (0.54) | CYP1A2TDP1PIK3CDDRD3HRH3 | |
| SCHEMBL7412564 | 0.78 | CYP1A2 (0.54) | CYP1A2TDP1PIK3CDDRD3HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 111 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3750894-B1 | UREA-SUBSTITUTED AROMATIC RING-LINKED DIOXAZOLINE COMPOUND, PREPARATION METHOD THEREFOR, AND USES THEREOF | BEIJING SCITECH MQ PHARMACEUTICALS LTD (CN) | 2024-04-03 | — | — | EP | claimed |
| EP-3590941-B1 | UREA-SUBSTITUTED AROMATIC RING-LINKED DIOXANE-QUINAZOLINE AND -LINKED DIOXANE-QUINOLINE COMPOUNDS, PREPARATION METHOD THEREFOR AND USE THEREOF | BEIJING SCITECH MQ PHARMACEUTICALS LTD (CN) | 2023-11-22 | — | — | EP | claimed |
| EP-3750893-B1 | DIOXAZOLINE COMPOUND, PREPARATION METHOD THEREFOR, AND USES THEREOF | BEIJING SCITECH MQ PHARMACEUTICALS LTD (CN) | 2023-04-19 | — | — | EP | claimed |
| EP-3862354-A1 | INDOLOPYRIDINES AS EG5 KINESIN MODULATORS | 4SC AG (DE) | 2021-08-11 | — | — | EP | claimed |
| US-10980809-B2 | Urea-substituted aromatic ring-linked dioxane-quinazoline and -linked dioxane-quinoline compounds, preparation method therefor and use thereof | BEIJING SCITECH-MQ PHARMACEUTICALS LIMITED (CN) | 2021-04-20 | — | — | US | claimed |
| EP-2824105-B1 | Indolopyridines as Eg5 kinesin modulators | 4SC AG (DE) | 2021-03-31 | — | — | EP | claimed |
| CN-111788207-B | Dioxane quinoline compound and preparation method and application thereof | 北京赛特明强医药科技有限公司 | 2021-03-23 | — | — | CN | claimed |
| CN-111757885-B | Urea-substituted aromatic ring-connected dioxane quinoline compound and preparation method and application thereof | 北京赛特明强医药科技有限公司 | 2021-01-29 | — | — | CN | claimed |
| US-20200399285-A1 | DIOXINOQUINOLINE COMPOUNDS, PREPARATION METHOD AND USES THEREOF | ACCSALUS BIOSCIENCES LIMITED (VG) | 2020-12-24 | — | — | US | claimed |
| US-20200399284-A1 | UREA-SUBSTITUTED AROMATIC RING-LINKED DIOXINOQUINOLINE COMPOUNDS, PREPARATION METHOD AND USES THEREOF | BEIJING SCITECH-MQ PHARMACEUTICALS LIMITED (CN) | 2020-12-24 | — | — | US | claimed |
| US-20090233902-A1 | INDOLOPYRIDINES AS EG5 KINESIN MODULATORS | 4SC AG (DE) | 2009-09-17 | — | — | US | claimed |
| CN-101389629-A | Indolopyridines as EG5 kinesin modulators | 4SC AG (DE) | 2009-03-18 | — | — | CN | claimed |
| CN-101389628-A | Indolopyridines as EG5 kinesin modulators | 4SC AG (DE) | 2009-03-18 | — | — | CN | claimed |
| EP-2033962-A1 | Tetracyclic indolopyridines as EG5 inhibitors | 4SC AG (DE) | 2009-03-11 | — | — | EP | claimed |
| US-20080108613-A1 | Pyrazolopyrimidine Compounds as Antitumor Agents | ASTRAZENECA AB (SE) | 2008-05-08 | — | — | US | claimed |
| CN-101124228-A | Pyrazolopyrimidine compounds as antitumor agents | ASTRAZENECA AB (SE) | 2008-02-13 | — | — | CN | claimed |
| EP-1838712-A1 | PYRAZOLOPYRIMIDINE COMPOUNDS AS ANTITUMOR AGENTS | AstraZeneca AB (SE) | 2007-10-03 | — | — | EP | claimed |
| WO-2006064196-A1 | PYRAZOLOPYRIMIDINE COMPOUNDS AS ANTITUMOR AGENTS | ASTRAZENECA AB (SE) | 2006-06-22 | — | — | WO | claimed |
| US-6156752-A | Optically active 1,4-dihydropyridine compounds as bradykinin antagonists | PFIZER INC (US) | 2000-12-05 | — | — | US | claimed |
| EP-0899261-A1 | Optical active 1,4-dihydropyridine compounds as bradykinin antagonists | PFIZER INC. (US) | 1999-03-03 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200399284-A1 | UREA-SUBSTITUTED AROMATIC RING-LINKED DIOXINOQUINOLINE COMPOUNDS, PREPARATION METHOD AND USES THEREOF | RET, BRAF, RAF1 | CYP1A2 130/4885TDP1 2064/4885PIK3CD 1450/4885 |
| US-10980809-B2 | Urea-substituted aromatic ring-linked dioxane-quinazoline and -linked dioxane-quinoline compounds, preparation method therefor and use thereof | BRAF, RAF1, ARAF | CYP1A2 90/4885TDP1 1909/4885PIK3CD 1190/4885 |
| US-20090233902-A1 | INDOLOPYRIDINES AS EG5 KINESIN MODULATORS | KIF5A, KIF5C, KIF5B | CYP1A2 3131/4885TDP1 503/4885PIK3CD 578/4885 |
| US-20200399285-A1 | DIOXINOQUINOLINE COMPOUNDS, PREPARATION METHOD AND USES THEREOF | KDR, MET, ABL1 | CYP1A2 49/4885TDP1 2619/4885PIK3CD 511/4885 |
| US-20080108613-A1 | Pyrazolopyrimidine Compounds as Antitumor Agents | ERBB2, ERBB3, ERBB4 | CYP1A2 1191/4885TDP1 2574/4885PIK3CD 305/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.